Enzyme therapy in Gaucher disease type 1: Effect of neutralizing antibodies to acid β-glucosidase

Blood

Volumn 90, Issue 1, 1997, Pages 43-48

  Ponce, Elvira ^a   Moskovitz, Jay ^a   Grabowski, Gregory ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC LINKAGE; HEPATOSPLENOMEGALY; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; SPLENECTOMY; TREATMENT OUTCOME;

EID: 0030908645     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.43     Document Type: Article

References (19)

1. Beutler E, Grabowski GA: Glucosylceramide lipidoses: Gaucher disease, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York. NY, McGraw-Hill, 1995, p 2641
2. Grabowski GA, Saal H, Wenstrup RJ, Barton NW: Gaucher disease: A prototype for molecular medicine. Crit Rev Hematol Oncol 23:25, 1996
3. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE: Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464, 1991
4. Grabowski GA, Barton NW, Pastores G, Banerjee TK, McKee A, Parker C, Schiffmann R, Dambrosia JM, Hill SC, Brady RO: Enzyme therapy in Gaucher disease type 1: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122:33, 1995
5. Pastores G, Sibille A, Grabowski GA: Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in thirty-three patients treated for six to twenty-four months. Blood 82:408, 1993
6. Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, Van Weely S, von dem Borne AE, van Oers MH: Individualized low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345:1474, 1995
7. Figueroa ML, Rosenbloom BE, Kay A, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E: A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 327:1632, 1992
8. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A: Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells, Molecules Dis 22:101, 1996
9. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC, Miller SPF, Brady RO, Barton NW: Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96:629, 1995
10. Richards S, Olson TA, McPherson JM: Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82:1402, 1993
11. Grace ME, Newman KM, Scheinker V, He G, Berg-Fussman A, Grabowski GA: Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J Biol Chem 269:2283, 1994
12. Beutler E, Gelbart T, West C: The facile detection of the nt 1226 mutation of glucocerebrosidase by 'mismatched' PCR. Clin Chim Acta 194:161, 1990
13. Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayor JA, Barranger JA, Ginns EI: A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med 316:570, 1987
14. Beutler E, Gelbart T, Kuhl W, Sorge J, West C: Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci USA 88:10544, 1991
15. He G, Grabowski GA: Gaucher disease: A G(+1) to A(+1) IVS2 splice donor site mutation causing exon 2 skipping in the acid beta-glucosidase mRNA. Am J Hum Genet 51:810, 1992
16. Tiarks C, Pechet L, Humphreys RE: Development of anti-idiotypic antibodies in a patient with factor VIII autoantibody. Am J Hematol 32:217, 1989
17. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy J: Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 97:1382, 1996
18. Xu Y, Ponce E, Sun Y, Leonova T, Bove K, Witte DP, Grabowski GA: Tissue distribution and half-lifes of intravenously administered alglucerase. Pediatr Res 39:313, 1996
19. Osiecki-Newman K, Fabbro D, Legler G, Desnick RJ, Grabowski GA: Human acid beta-glucosidase: Use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites. Biochim Biophys Acta 915:87, 1987